

Notes:

1. The figures have been re-grouped, re-cast and re-arranged wherever necessary;
2. The financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors at their meetings held on 24th October, 2008;
3. As per revised clause 41 of the listing agreement, the Company has opted to publish only consolidated financial results. The stand-alone financial results are available for perusal on the Company's website as well as on the stock exchanges' websites as stated below: www.dishmangroup.com, www.bseindia.com, and www.nse-india.com
4. The Statutory Auditors have carried out a "Limited Review" of the stand-alone financial results of the Company for the quarter ended 30th September, 2008.
5. Exceptional item represents losses due to changes in foreign exchange rates which have been accounted for in accordance with AS 11 – 'Changes in foreign exchange rates' issued by ICAI.
6. Details of Number of Investor complaints for the quarter ended 30th September, 2008: beginning - NIL, received- 5, resolved- 5, pending- NIL as at 30th September, 2008;
7. The business segments of the Company comprise of the followings:

Segment	Description of the activity
CRAMS	Contract Research and Manufacturing Segment under long term supply agreements
MM	Bulk Drugs, Intermediates, Quats, and Speciality Chemicals

8. Consolidated financial results comprise the results of the parent Company, Dishman Pharmaceuticals and Chemicals Limited and its subsidiaries viz. Dishman Infrastructure Limited, Dishman Europe Limited., Dishman Switzerland Limited, Innovative Ozone Services Inc. (IO₃S), Dishman USA Inc., Dishman Netherlands B. V. (formerly known as "Pharma Syn B. V."), Dishman Holland B.V., Dishman Africa (Proprietary) Limited, Dishman International Trading (Shanghai) Co. Ltd., Dishman FZE, Carbogen Amcis Ltd. (formerly known as "Synprotec DCR Ltd."), CARBOGEN AMCIS AG, Dishman Pharma Solutions AG, Switzerland, Dishman Pharmaceuticals & Chemicals (Shanghai) Co. Ltd., Carbogen Amcis (India) Limited, Dishman Australasia Ltd., Dishman Japan Limited (85% holding by Dishman), three joint venture Companies., namely Schutz-Dishman Biotech Ltd.(22.33% holding by Dishman), CAD Middle East Pharmaceutical Industries, LLC. (30% holding by Dishman) and Dishman Arabia Ltd., (50% holding by Dishman) and one associate company namely, Bhadr-Raj Holdings Pvt. Ltd. (40% holding by Dishman) as per relevant Accounting Standards.

On behalf of the Board

Sd/-

J. R. Vyas

Managing Director

Place: Ahmedabad

Date: 24th October 2008